Neurofibromatosis Type 1

Back

Practice Essentials

Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder that is characterized by cutaneous findings, most notably café-au-lait spots and axillary freckling (see the images below), by skeletal dysplasias, and by the growth of both benign and malignant nervous system tumors, most notably benign neurofibromas.



View Image

Café-au-lait spots in a 4-year-old boy.



View Image

Axillary freckles.

Signs and symptoms

Signs and symptoms of NF1 can vary widely from patient to patient. The earliest clinical finding usually seen in children with NF1 is multiple café-au-lait spots. These may be present at birth or may appear over time, frequently increasing in size and number throughout childhood.

Axillary or inguinal freckles are rarely present at birth, but appear during childhood through adolescence. Subcutaneous or cutaneous neurofibromas are seen rarely in young children but appear over time in older children, adolescents, and adults.

Other signs and symptoms may include the following:

See Clinical Presentation for more detail.

Diagnosis

Clinical diagnosis requires the presence of at least 2 of 7 criteria to confirm the presence of NF1. Many of these signs do not appear until later childhood or adolescence; thus, confirming the diagnosis often is delayed despite a suspicion of NF1. The 7 clinical criteria used to diagnose NF1 are as follows, in the absence of alternative diagnoses:

See Workup for more detail.

Management

Medical care

There is no cure for neurofibromatosis. Patients should be routinely monitored for complications. Annual examinations should include the following:

Chemotherapy, radiation therapy, or both may be used to treat cancerous tumors, but with the avoidance of radiation therapy when possible, due to the incurred increased risk of secondary malignancies.

Surgical care

Surgery can be used to remove tumors that cause pain or a loss of function. Neurofibromas that press on vital structures, obstruct vision, or grow rapidly deserve immediate attention.

Orthopedic intervention is indicated for rapidly progressive scoliosis and for some severe bony defects.

See Treatment and Medication for more detail.

Background

Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder that commonly is associated with cutaneous, neurologic, and orthopedic manifestations. It is the most frequent of the so-called hamartoses, conditions characterized by non-neoplastic tissue overgrowth.

NF type 1 (NF1) is differentiated from central NF or NF type 2 in which patients demonstrate a relative paucity of cutaneous findings but have a high incidence of meningiomas and acoustic neuromas (which are frequently bilateral). NF1 has a lower incidence of central nervous system (CNS) tumors than NF2. However, complications of NF1 can include visual loss secondary to optic nerve gliomas, spinal cord tumors, scoliosis, vascular lesions, and long-bone abnormalities.

Pathophysiology

The manifestations of NF1 result from a mutation in or deletion of the NF1 gene. The gene product neurofibromin serves as a tumor suppressor; decreased production of this protein results in the myriad of clinical features.

Frequency

The estimated incidence of NF1 is 1 in 3000, but the actual frequency may be higher because of less than complete ascertainment of mildly affected individuals. Approximately half of affected individuals represent first cases in the family as a result of a new genetic event or mutation.

Mortality/Morbidity

Life expectancy in NF1 is approximately 8 years less than the general population.[1]

Lifetime risks for both benign and malignant tumors are increased in NF1-affected individuals.

Cutaneous or subcutaneous neurofibromas, optic nerve gliomas, dumbbell-shaped spinal cord tumors, and brain tumors, particularly gliomas, represent some of the well-recognized nerve-related neoplasms.

Adolescence for both genders may precipitate the development of subcutaneous and cutaneous neurofibromas. Increase in the size of existing neurofibromas and the appearance of new neurofibromas during pregnancy is a frequent observation in women with NF1.[2]

Plexiform neurofibromas, which are generally larger, more diffuse, and locally invasive, are seen in more than one fourth of patients with NF1[3] and can present difficult management decisions. The management of close surveillance versus intervention is often debated, with the recognition that complete resection of a plexiform neurofibroma without residual functional deficits is rarely possible. On the other hand, debulking or partial resection of plexiform neurofibromas may be undertaken for cosmetic purposes or if progressive functional consequences are anticipated.

Gliomas in patients with NF1 tend to be lower grade and have a more favorable prognosis than in patients without NF1, with pilocytic astrocytomas and low-grade astrocytomas (subtype intermediate) being most common.[4] However, diffusely infiltrating astrocytomas are also seen in a subset of patients and need to be managed accordingly.

Malignant peripheral nerve sheath tumors (MPNSTs) and neurosarcomas are not uncommon in adolescents and adults with NF1, with an approximate lifetime risk of 10%. These malignancies frequently arise from large plexiform neurofibromas or extensive peripheral nerve lesions. MPNSTs in patients with NF1 carry a poorer prognosis than in patients without this condition; tumor volume is an independent prognostic indicator.[5]

More than 1% of patients with NF1 develop an indolent symmetric sensory axonal neuropathy. However, some cases of polyneuropathy occur in association with diffuse nerve root lesions or MPNSTs.

Gastrointestinal stromal tumors (GIST), often multiple with a predilection for the proximal small bowel, may be seen in patients with NF1. Therefore, there should be a high index of suspicion for a GIST in a patient who presents with GI bleeding or intestinal obstruction.[6] Gene mutations typically seen in sporadic GISTs leading to malignant transformation are rarely identified in the GISTs removed from patients with NF1.[7] Instead, activation of the Ras-MAPK pathway and loss of heterozygosity of specific chromosomal regions may underlie the development of GISTs in patients with NF1.[8]

Learning disabilities with or without attention deficit hyperactivity disorder (ADHD) are seen in approximately 40% of NF1-affected individuals. A much smaller percentage experience more significant cognitive difficulties such as mild or moderate mental retardation. Furthermore, a recent population based study reported a prevalence of autism spectrum disorder in 30%.[9]

Scoliosis in NF1 is often mild, but a subset of children younger than 10 years develop a more rapidly progressive form of scoliosis that requires aggressive intervention.

Bony abnormalities may be clinically silent, with radiographic evidence of long bone intramedullary fibrosis, cortical thinning, or vertebral dural ectasias often found incidentally. Sphenoid bone dysplasia and long-bone bowing or pseudarthrosis are common features of NF1. In the past, congenital tibial pseudarthrosis led to below-the-knee amputation; however, recent advances in orthopedic management with limb-sparing procedures have decreased the need for such drastic procedures.

Osteoporosis with statistically significant decreases in bone mineral density can be identified in individuals with NF1, perhaps even as early as childhood.[10] Whereas a number of metabolic pathways impacting bone metabolism have been implicated in the pathogenesis of bone abnormalities in people with NF, studies in children and teens with NF have provided evidence for increased rates of bone resorption as a likely cause for osteopenia.[11]

Emerging evidence shows that vitamin D deficiency combined with a higher than normal bone turnover contributes to decreased bone mineral density (BMD) in patients with NF1.[12] One study looking at adults with NF1 (mean age, early 40s), showed that 50% had osteopenia and 19% had frank osteoporosis. Males were more likely than females to have reduced BMD; 56% of patients had a low 25-hydroxy-vitamin D while 34% had elevated parathyroid hormone.[13] Judicious vitamin D supplementation may prove beneficial for patients with NF1 who have vitamin D deficiency or evidence of osteopenia.

Hypertension in NF1 can be seen at any age, with many adults with NF1 manifesting the usual essential form of hypertension. However, any person with NF1 and high blood pressure must be evaluated carefully for 2 alternative causes of hypertension (see Prognosis).

Pheochromocytomas are not rare (< 5%) in NF1 and can cause severe, fluctuating hypertension.

Vascular stenosis (ie, renal artery stenosis secondary to fibromuscular dysplasia) also may result in hypertension that may not respond well to standard pharmacologic management.

Other vascular lesions, especially in the central nervous system, such as vascular ectasias, stenoses, moyamoya disease, and aneurysms, occur more frequently in patients with NF1. Rarely, coronary artery aneurysms are identified in symptomatic or even asymptomatic individuals with NF1.[14]

Short stature is common in NF1; affected individuals are often shorter than their unaffected siblings.

Macrocephaly is common in NF1 and should not cause undo alarm if present in affected infants or young children, unless serial head circumference measurements confirm the rapid crossing of percentiles.

Chiari type 1 malformations are seen with increased frequency in the NF1 population.

Puberty usually occurs at a normal age, but precocious puberty with growth acceleration may occur in a small number of individuals. When precocious puberty is present, the patient must be evaluated for a chiasmal lesion causing disruption of the hypothalamic-pituitary axis.

Race-, sex-, and age-related demographics

All races and ethnic backgrounds are affected equally. However, evidence indicates that the risk for optic nerve glioma is lower in African Americans than in Caucasians and Hispanics.

Males and females are affected equally with this autosomal dominant condition. However, one study showed that female patients with NF1-associated optic glioma were twice as likely to undergo brain magnetic resonance imaging for visual symptoms and three times more likely to require treatment for visual decline than their male counterparts.[15]

Scoliosis may be especially severe in young girls compared to their male counterparts.

Although the genetic change causing NF1 is present at conception, clinical manifestations may appear slowly over many years.

Diagnosis often is made earlier in children born to an NF1-affected parent; the clinical criteria for diagnosis are fulfilled more easily, and the clinician may be more attuned to this possible diagnostic concern.

If an at-risk individual reaches the age of 10 years without meeting the diagnostic criteria for NF1, he or she is unlikely to be affected.

History

Clinical diagnosis requires the presence of at least 2 of 7 criteria to confirm the presence of neurofibromatosis, type 1. Many of these signs do not appear until later childhood or adolescence, and thus confirming the diagnosis often is delayed despite a suspicion of NF1. The 7 clinical criteria used to diagnose NF1 are as follows:

Physical

The earliest clinical finding usually seen in children with NF1 is multiple café-au-lait spots. These may be present at birth or may appear over time, frequently increasing in size and number throughout childhood (See the image below).



View Image

Café-au-lait spots in a 4-year-old boy.

In adults, café-au-lait spots tend to fade and may be less obvious on clinical examination.

Axillary or inguinal freckles are rarely present at birth, but appear during childhood through adolescence (See the images below).



View Image

Axillary freckles.



View Image

Inguinal freckles.

Subcutaneous or cutaneous neurofibromas are seen rarely in young children but appear over time in older children, adolescents, and adults (See the image below).



View Image

Multiple neurofibromas in a 28-year-old man.

Deep lesions may be detected only through palpation, whereas cutaneous lesions may appear initially as small papules on the trunk, extremities, scalp, or face.

Puberty or pregnancy may be associated with an increased number of neurofibromas as well as more rapid growth of preexisting lesions.

Plexiform neurofibromas are more diffuse growths that can be locally invasive and quite deep; they may be associated with bony erosion and pain (See the image below).



View Image

Plexiform neurofibroma of the right thigh.

Plexiform neurofibromas also may be accompanied by overlying hyperpigmentation or hypertrichosis.

Rarely, rapid growth of a neurofibroma may occur and can be suggestive of malignant transformation.

Optic pathway tumors, typically histologically low-grade pilocytic astrocytomas, occur in 15-20%. They may be clinically silent, but can be symptomatic in 30-50%, primarily in children younger than 6 years.[17] Gender may be a major prognostic factor, as females have been reported to have a three-fold risk to require treatment for visual decline than males.[15]

Asymmetric, noncorrectable visual loss is the most common presenting symptom, but subtle peripheral field defects, color discrimination difficulties, optic nerve pallor, or proptosis may occur without visual acuity problems.

Some older children and adolescents may present with worsening vision secondary to a slow-growing optic nerve glioma (ONG) and, therefore, monitoring for visual difficulties should continue throughout childhood and adulthood. Adults may have a visually insignificant optic nerve glioma detected incidentally on a head imaging study.

Posterior optic pathway tumors with hypothalamic encroachment may present as precocious puberty.

Although Lisch nodules occasionally can be seen with a direct or indirect ophthalmoscope, especially in individuals with light-colored irides, they are usually not readily visible without using a slit lamp (See the image below).



View Image

Lisch nodules.

Choroidal abnormalities with a patchy appearance may also be noted on funduscopic examination using infrared monochromatic light. Retinal corkscrew vascular changes have also been described in some patients with NF1.

Sphenoid bone dysplasia is usually asymptomatic, but occasionally can be associated with herniation through the bony defect. In the occasional patient with a plexiform neurofibroma of the eyelid, ipsilateral sphenoid dysplasia is frequently present.

Congenital pseudarthrosis may be evident at birth, with bowing of the tibia being the most typical presentation (See the image below).



View Image

Radial and ulnar bowing and obliteration of the intramedullary spaces.

Thinning and angulation of long bones can occur throughout early childhood and adolescence, with prominence of the anterior tibia and progressive deformity. Less commonly, bowing of the forearm can occur.

Scoliosis with or without kyphosis may become evident in childhood or adolescence. When found in a child younger than 10 years, it is associated with a much poorer prognosis and is likely to progress rapidly. Scoliosis detected during adolescence still should be monitored clinically, but is much less likely to require orthopedic intervention.

Blood pressure should be checked during every clinical visit because of the distinct possibility of alternative causes of hypertension in NF1.

Head circumference should be monitored throughout the first 3 years of life, as with any child. Relative macrocephaly should not cause alarm, unless serial measurements suggest rapid growth with crossing of 2 or more percentile lines.

Causes

NF1 is an autosomal dominant condition caused by decreased production of the protein neurofibromin, which has a putative tumor suppressor function. Only one NF1 gene need be deleted or mutated to produce the condition.

The NF1 gene has been localized to the long arm of chromosome 17; more than 250 mutations leading to protein truncation have been identified in affected individuals. A more severe phenotype has been observed in a subset of patients with a complete gene deletion.

The precise role of neurofibromin is not fully understood, but the multitude of clinical effects suggests that this gene product has diverse functions in various tissues.

Mutations in another gene (SPRED1) have been identified in a subset of patients described to have an NF-like syndrome, also known as Legius syndrome.[18] Individuals with a SPRED1 mutation may be incorrectly diagnosed with NF1 based on the presence of multiple café-au-lait spots and axillary or inguinal freckles, but these patients do not go on to develop the neurofibromas or Lisch nodules that are found in most adults with true NF1.

Laboratory Studies

The diagnosis of NF1 is usually made clinically, however, molecular testing may be helpful for younger patients with a single clinical finding, such as multiple café-au-lait spots in the absence of a positive family history.

Legius Syndrome should be suspected in patients with macrocephaly, café-au-lait spots and axillary freckling and no NF1 tumors (neurofibromas, lisch nodules, optic gliomas or plexiform neurofibromas). Given that NF1 is more common, testing should start with NF1 sequencing and reflex to SPRED1 if negative.

Neurofibromatosis type 1 (NF1) may be diagnosed by either of 2 methods during the prenatal period.

Urinary free catecholamines (norepinephrine and epinephrine) as well as their metabolites (normetanephrine, metanephrine and vanillyl-mandelic acid) measured on a 24-hour urine collection are good biochemical screening tests for a suspected pheochromocytoma.[20]

Plasma catecholamines may also be measured using liquid chromatography. Measurement of free plasma metanephrine is more sensitive in detection of a pheochromocytoma than plasma catecholamines.[21]

Imaging Studies

Radiography

Plain films may detect a variety of subtle and not so subtle bony abnormalities associated with NF1. See the image below.



View Image

Radial and ulnar bowing and obliteration of the intramedullary spaces.

Radiographs should be obtained when clinical findings suggest possible modeling defects of the long bones or ribs, possible bony erosion secondary to an adjacent plexiform neurofibroma, signs of scoliosis, or bone pain.

MRI or CT scan

The use of routine screening brain neuroimaging in patients with NF1 is controversial. This is mainly due to the lack of consistent evidence that early detection reduces the rate of vision loss and that identifying and repeating interval imaging of asymptomatic optic pathway gliomas that never progress exposes young children to repeated sedations.[17]  However, there is emerging evidence that early radiological identification prior to the development of vision loss may lead to improved future visual outcomes.[22]  Furthermore, a negative MRI at a young age may predict the lack of the development of symptomatic optic nerve gliomas in the future.[22]

Some clinicians prefer to perform a baseline CT scan or MRI in children or adults at the time of diagnosis, subsequently recommending another imaging study only if neurological problems arise. Other clinicians feel that baseline studies are of limited value, since detecting an asymptomatic optic nerve glioma would probably not prompt medical intervention.

MRI is the preferred diagnostic head imaging study in NF1.

Brain CT scan or MRI should be considered to evaluate ventricular size when increasing head circumferences is noted in an infant or young child. Rarely, hydrocephalus and/or a Chiari type 1 malformation are seen in children and even adults with NF1.

Other Tests

Electroencephalogram (EEG) is indicated in patients with symptoms suggestive of seizures. Seizures are reported more often in patients with NF1 than in the general population, occurring in between 4 and 7%.

MRI alone is generally sufficient for medical and/or surgical decision making. Occasionally, myelography is needed to clarify the extent of a spinal cord tumor.

Procedures

Slit-lamp examination by an experienced ophthalmologist can provide key diagnostic information in older children and adults who have only a single clinical criterion such as multiple café-au-lait spots.

Histologic Findings

Neurofibromas are generally well-differentiated tumors that contain elongated spindle-shaped cells as well as pleomorphic fibroblast-like cells. Rarely, inflammatory cells may be seen in these otherwise benign-appearing lesions.

Optic gliomas also are indolent, generally very low-grade lesions. In fact, optic nerve lesions associated with NF1 are less aggressive and respond more favorably to current therapies than optic nerve tumors in the general population.

Occasionally, a neurofibroma (typically large or deep plexiform neurofibroma or peripheral nerve sheath tumor residing within the brachial or pelvic plexus) undergoes malignant transformation to a neurofibrosarcoma. Unlike benign neurofibromas, neurofibrosarcomas are characteristically hypercellular with giant cells, increased numbers of mitoses, and vascular proliferation.

Because collections of malignant cells may be present between larger masses of benign cells in a plexiform neurofibroma, examining a plexiform tumor carefully (ie, taking samples from multiple regions to confirm that it is indeed benign) is essential.

Medical Care

For individuals diagnosed with neurofibromatosis type 1 (NF1), routine examinations should focus on the potential complications.

Cutaneous examination performed at each visit should look for new neurofibromas or progression of preexisting lesions. Plexiform neurofibromas may be locally invasive, therefore clinical evaluation should be directed at determining the extent of involvement and detecting evidence of bony erosion or nerve entrapment.

Skeletal involvement, including scoliosis, hemihypertrophy, or long-bone modeling defects, should be documented.

Blood pressure should be checked at each visit and hypertension treated promptly if detected. Hypertension workup should include evaluation for pheochromocytoma (ie, measurement of urinary catecholamines and metanephrines) and testing for renal artery stenosis. Percutaneous transluminal renal artery angioplasty may, in some cases, effectively treat renal artery stenosis secondary to fibromuscular dysplasia.

Interval history should focus on subtle sensory or motor symptoms such as paresthesia, radiculopathy, weakness, or muscle atrophy.

Removal of neurofibromas for medical or cosmetic indications is one of the most common procedures on individuals with NF1.

Although laser treatment has been used for various cutaneous, hyperpigmented lesions (eg, port-wine stains, tattoos), it has not yet proven successful in permanent removal of café-au-lait spots.

Use of chemotherapy to treat malignant peripheral nerve sheath tumors (MPNSTs) that are unresectable or metastatic has been debated for a number of years, with less than optimal outcomes using a variety of combinations of agents. More recently, in vitro studies looking at a broader range of agents targeting the Ras and/or other relevant pathways have shown some promising results.

Surgical Care

Surgical resection of neurofibromas can be accomplished, but plastic surgery consultation is advisable for areas of great cosmetic concern such as the face. Resection is the treatment of choice for pheochromocytomas.[33]

Neurofibromas that press on vital structures, obstruct vision, or grow rapidly deserve immediate attention.

Plexiform neurofibromas may be difficult to approach surgically, often recurring after resection because of residual tumor cell collections deep in soft tissues. Surgeons must realize that removing some of these lesions can result in substantial blood loss and must plan accordingly.

Symptomatic peripheral nerve sheath tumors located along the nerves of the brachial or pelvic plexus sometimes require surgical intervention with the very real potential for postoperative nerve dysfunction. Added to this is the risk for malignant transformation that carries with it a very poor prognosis; the decision to operate requires much thought and careful consideration. One should always weigh the potential diagnostic benefits taking into account one's index of suspicion for malignancy, against the potential risks for long-term neurologic sequelae.

For many patients, neurofibromas on the scalp, along the hairline, or around the waist where clothes rub can cause great irritation and discomfort. Therefore, removing these should not be considered cosmetic but a necessary medical procedure.

Resection of spinal cord tumors is difficult but often necessary to prevent progressive paraplegia or quadriplegia.

Orthopedic intervention is indicated for rapidly progressive scoliosis and for some severe bony defects.

Some hypertensive patients with renal artery stenosis require surgical resection and repair instead of or following angioplasty.

Resection of a pheochromocytoma requires preoperative treatment with an alpha-blocker (preferably a selective postsynaptic alpha1-receptor antagonist) to offset the effects of catecholamine release during surgical manipulation of the tumor.[35]

Consultations

The neurologist serves as a key consultant and provides valuable information concerning changes in neurological status by performing a complete, focused examination.

The neurosurgeon serves as an expert consultant when a spinal cord or brain tumor is identified and works closely with the neurologist to determine the optimal timing and best surgical approach on an individual basis.

The ophthalmologist serves as a valuable member of the NF1 consultation team, evaluating patients on an annual basis for changes in visual acuity, field defects, or appearance of Lisch nodules.

The geneticist provides information concerning diagnosis, diagnostic testing, inheritance, and risks for recurrence in future children. Family planning options and prenatal diagnosis may be addressed in this clinical setting.

The orthopedist is a key consultant for the many NF1-related bone abnormalities (eg, scoliosis, pseudarthrosis, hemihypertrophy, bony erosion by plexiform neurofibromas).

The developmental pediatrician may be an invaluable resource in evaluating a child with NF1 and learning disabilities, attention deficit hyperactivity disorder, or autism spectrum disorder.

In addition to these most frequently used consultants, patients may need to see others for specific NF1 concerns. Examples include the following:

Activity

No activity restrictions are necessary, except for an individual with specific orthopedic concerns (as recommended by the consulting surgeon).

Medication Summary

No known medical therapies are beneficial to patients with NF1. Several drug trials have been initiated, looking for medications that slow or halt the growth of neurofibromas. Thus far, none of these medications have demonstrated significant benefit, although various research trials involving chemotherapeutic and other agents are underway in an attempt to slow the growth of plexiform neurofibromas.

For a small subset of patients with pruritus due to cutaneous neurofibromas, diphenhydramine may provide some temporary relief. Such patients also are encouraged to avoid hot showers and baths, since hot temperatures may exacerbate itching.

Treatment with carboplatin shows efficacy in controlling the growth of visually significant optic gliomas.

Diphenhydramine (Aler-Dryl, Benadryl, Diphen, Altaryl)

Clinical Context:  First-generation antihistamine with anticholinergic effects that binds to H1 receptors in the CNS and the body.

Competitively blocks histamine from binding to H1 receptors. Has significant antimuscarinic activity and penetrates CNS, which causes pronounced tendency to induce sedation.

Approximately half of those treated with conventional doses experience some degree of somnolence. A small percentage of children paradoxically respond to diphenhydramine with agitation.

For symptomatic relief of pruritus caused by release of histamine in inflammatory reactions.

Class Summary

These agents may control itching by blocking effects of endogenously released histamine.

Carboplatin

Clinical Context:  Alkylating agent that has been used extensively in treatment of ovarian cancer, but with efficacy in treatment of optic nerve lesions in combination with vincristine sulfate.

Class Summary

These agents inhibit cell growth and proliferation. The agent carboplatin has been used in the treatment of visually significant optic nerve gliomas.

Further Outpatient Care

Although patients with neurofibromatosis type 1 (NF1) can be cared for in the primary care setting, additional medical concerns need to be addressed on a routine basis.

An outline of reasonable guidelines in caring for patients with NF1 is as follows:

Further Inpatient Care

Hospitalization may be necessary for major surgical procedures and workup of uncontrolled hypertension.

Many minor surgical procedures (eg, removal of cutaneous neurofibromas) may be done in an outpatient surgical setting.

Complications

Complications may include the following:

Prognosis

Although most individuals with NF1 lead relatively long and healthy lives, the overall life expectancy may be reduced by on average 8 years. The major causes for this increased morbidity and subsequent mortality are hypertension, sequelae of spinal cord lesions, and malignancy.

Prompt attention to complications of NF1 and early detection of medical problems may significantly reduce the overall morbidity and mortality rates.

Patient Education

Patients and their families may be referred to NF-specific national and regional support groups for continuous updates on treatment advances and for emotional support. The previous National NF Foundation, Inc, renamed Children's Tumor Foundation, can be accessed via web at www.ctf.org or by phone at 1-800-323-7938. Neurofibromatosis, Inc is another support and resource group (www.nfnetwork.org; 1-800-942-6825).

Inform patients of symptoms that would require immediate medical attention, including headaches increasing in intensity or frequency or focal neurological deficits.

What is neurofibromatosis type 1 (NF1)?What are the signs and symptoms of neurofibromatosis type 1 (NF1)?What are the diagnostic criteria for neurofibromatosis type 1 (NF1)?What is involved in the monitoring of patients with neurofibromatosis type 1 (NF1)?What is the role of surgery in the management of neurofibromatosis type 1 (NF1)?How is neurofibromatosis type 1 (NF1) differentiated from central neurofibromatosis or neurofibromatosis type 2 (NF2)?What is the pathophysiology of neurofibromatosis type 1 (NF1)?What is the incidence of neurofibromatosis type 1 (NF1)?What is the life expectancy of patients with neurofibromatosis type 1 (NF1)?Which nerve-related neoplasms are associated with neurofibromatosis type 1 (NF1)?Which factors may precipitate the development of subcutaneous and cutaneous neurofibromas?How prevalent are plexiform neurofibromas in neurofibromatosis type 1 (NF1)?What is the prognosis of gliomas in neurofibromatosis type 1 (NF1)?What is the prognosis of malignant peripheral nerve sheath tumors (MPNSTs) and neurosarcomas in neurofibromatosis type 1 (NF1)?What is the prevalence of sensory axonal neuropathy in neurofibromatosis type 1 (NF1)?What are the signs of GI stromal tumors (GIST) in neurofibromatosis type 1 (NF1)?What is the prevalence of learning disabilities in patients with neurofibromatosis type 1 (NF1)?What is the skeletal morbidity of neurofibromatosis type 1 (NF1)?What are the manifestations of hypertension in neurofibromatosis type 1 (NF1)?What types of vascular lesions occur in patients with neurofibromatosis type 1 (NF1)?What are common complications of neurofibromatosis type 1 (NF1)?What are the racial predilections for neurofibromatosis type 1 (NF1)?How does the incidence of neurofibromatosis type 1 (NF1) vary by sex?At what age is neurofibromatosis type 1 (NF1) typically diagnosed?What are the clinical criteria used to diagnose neurofibromatosis type 1 (NF1)?What are physical findings characteristic of neurofibromatosis type 1 (NF1)?What are the physical findings of subcutaneous or cutaneous neurofibromas characteristic of neurofibromatosis type 1 (NF1)?Which physical findings of neurofibromatosis type 1 (NF1) are associated with puberty or pregnancy?Which physical findings are characteristics of plexiform neurofibromas in neurofibromatosis type 1 (NF1)?What are physical findings of optic pathway tumors characteristic of neurofibromatosis type 1 (NF1)?What are physical findings of bone abnormalities characteristic of neurofibromatosis type 1 (NF1)?What should be included in regular clinical visits for patients with neurofibromatosis type 1 (NF1)?What causes neurofibromatosis type 1 (NF1)?What conditions should be included in the differential diagnosis of neurofibromatosis type 1 (NF1)?What are the differential diagnoses for Neurofibromatosis Type 1?What is the role of lab studies in the workup of neurofibromatosis type 1 (NF1)?Which findings in the evaluation of neurofibromatosis type 1 (NF1) should raise suspicion of Legius syndrome?How is neurofibromatosis type 1 (NF1) diagnosed prenatally?What is the role of urine analysis in the workup of neurofibromatosis type 1 (NF1)?What is the role of radiography in the workup of neurofibromatosis type 1 (NF1)?What is the role of MRI or CT scan in routine screening of patients with neurofibromatosis type 1 (NF1)?What are the advantages of MRI for the diagnosis of neurofibromatosis type 1 (NF1)?What are the indications for MRI and CT scan in the workup of neurofibromatosis type 1 (NF1)?What is the role of electroencephalogram (EEG) in the workup of neurofibromatosis type 1 (NF1)?What is the role of a slit lamp exam in the evaluation of neurofibromatosis type 1 (NF1)?Which histologic findings are characteristic of neurofibromatosis type 1 (NF1)?What is the focus of routine exams for patients with neurofibromatosis type 1 (NF1)?What should be the focus of interval history in patients with neurofibromatosis type 1 (NF1)?What are the options for removal of neurofibromas in neurofibromatosis type 1 (NF1)?What is the role of laser treatment for neurofibromatosis type 1 (NF1)?What is the role of chemotherapy in the treatment of neurofibromatosis type 1 (NF1)?What is the role of surgery in the treatment of neurofibromatosis type 1 (NF1)?When is resection of spinal cord tumors indicated in neurofibromatosis type 1 (NF1)?When is orthopedic intervention indicated in the treatment of neurofibromatosis type 1 (NF1)?What are the indications for surgical resection in the treatment of neurofibromatosis type 1 (NF1)?Which specialist consultations are needed for the treatment of neurofibromatosis type 1 (NF1)?Which specialist consultations are needed to address specific concerns in neurofibromatosis type 1 (NF1)?Which activity modifications are used in the treatment of neurofibromatosis type 1 (NF1)?What is the role of drug treatment for neurofibromatosis type 1 (NF1)?Which medications in the drug class Antineoplastic agents are used in the treatment of Neurofibromatosis Type 1?Which medications in the drug class Antihistamines are used in the treatment of Neurofibromatosis Type 1?What are the guidelines for ongoing care of patients with neurofibromatosis type 1 (NF1)?When is inpatient care indicated for neurofibromatosis type 1 (NF1)?What are potential complications of neurofibromatosis type 1 (NF1)?What is the prognosis of neurofibromatosis type 1 (NF1)?What is included in patient education for neurofibromatosis type 1 (NF1)?

Author

David T Hsieh, MD, FAAP, Associate Professor of Pediatrics and Neurology, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Luis O Rohena, MD, MS, FAAP, FACMG, Chief, Medical Genetics, San Antonio Military Medical Center; Associate Professor of Pediatrics, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Professor of Pediatrics, University of Texas Health Science Center at San Antonio

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Kenneth J Mack, MD, PhD, Senior Associate Consultant, Department of Child and Adolescent Neurology, Mayo Clinic

Disclosure: Nothing to disclose.

Chief Editor

Amy Kao, MD, Attending Neurologist, Children's National Medical Center

Disclosure: Have stock (managed by a financial services company) in healthcare companies including Allergan, Cellectar Biosciences, CVS Health, Danaher Corp, Johnson & Johnson.

Additional Contributors

Ann M Neumeyer, MD, Medical Director, Lurie Center for Autism; Assistant Professor of Neurology, Harvard Medical School; Child Neurologist, Massachusetts General Hospital

Disclosure: Nothing to disclose.

Acknowledgements

The view(s) expressed herein are those of the author(s) and do not reflect the official policy or position of Brooke Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force, Department of Defense or the U.S. Government.

Beth A Pletcher, MD Associate Professor, Co-Director of The Neurofibromatosis Center of New Jersey, Department of Pediatrics, University of Medicine and Dentistry of New Jersey

Beth A Pletcher, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Medical Genetics, American Medical Association, and American Society of Human Genetics

Disclosure: Nothing to disclose.

References

  1. Wilding A, Ingham SL, Lalloo F, et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet. 2012. 49:264–9. [View Abstract]
  2. Dugoff L, Sujansky E. Neurofibromatosis type 1 and pregnancy. Am J Med Genet. 1996 Dec 2. 66(1):7-10. [View Abstract]
  3. Darrigo LG Jr, Geller M, Bonalumi Filho A, et al. Prevalence of plexiform neurofibroma in children and adolescents with type I neurofibromatosis. J Pediatr (Rio J). 2007 Nov-Dec. 83(6):571-3. [View Abstract]
  4. Rodriguez FJ, Perry A, Gutmann DH, et al. Gliomas in neurofibromatosis type 1: a clinicopathologic study of 100 patients. J Neuropathol Exp Neurol. 2008 Mar. 67(3):240-9. [View Abstract]
  5. Porter DE, Prasad V, Foster L, Dall GF, Birch R, Grimer RJ. Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma. 2009. 2009:756395. [View Abstract]
  6. Basile U, Cavallaro G, Polistena A, Giustini S, Orlando G, Cotesta D. Gastrointestinal and Retroperitoneal Manifestations of Type 1 Neurofibromatosis. J Gastrointest Surg. 2009 Jun 3. [View Abstract]
  7. Hegyi L, Thway K, Newton R, Osin P, Nerurkar A, Hayes AJ. Malignant myoepithelioma arising in adenomyoepithelioma of the breast and coincident multiple gastrointestinal stromal tumours in a patient with neurofibromatosis type 1. J Clin Pathol. 2009 Jul. 62(7):653-5. [View Abstract]
  8. Yamamoto H, Tobo T, Nakamori M, Imamura M, Kojima A, Oda Y. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q. J Cancer Res Clin Oncol. 2009 Jun. 135(6):791-8. [View Abstract]
  9. Garg S, Green J, Leadbitter K, Emsley R, Lehtonen A, Evans DG, et al. Neurofibromatosis Type 1 and Autism Spectrum Disorder. Pediatrics. 2013 Nov 4. [View Abstract]
  10. Brunetti-Pierri N, Doty SB, Hicks J, et al. Generalized metabolic bone disease in Neurofibromatosis type I. Mol Genet Metab. 2008 May. 94(1):105-11. [View Abstract]
  11. Stevenson DA, Schwarz EL, Viskochil DH, et al. Evidence of increased bone resorption in neurofibromatosis type 1 using urinary pyridinium crosslink analysis. Pediatr Res. 2008 Jun. 63(6):697-701. [View Abstract]
  12. Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, Friedrich RE, et al. High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int. 2010 Jan. 21(1):119-27. [View Abstract]
  13. Tucker T, Schnabel C, Hartmann M, Friedrich RE, Frieling I, Kruse HP. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet. 2009 Apr. 46(4):259-65. [View Abstract]
  14. Smith A, Araoz PA, Kirsch J. Coronary arterial aneurysms in neurofibromatosis 1: case report and review of the literature. J Thorac Imaging. 2009 May. 24(2):129-31. [View Abstract]
  15. Diggs-Andrews KA, Brown JA, Gianino SM, et al. Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol. 2014. 75:309-16. [View Abstract]
  16. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997. 278:51-7. [View Abstract]
  17. Listernick R, Ferner RE, Liu, GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis-1: Controversies and recommendations. Ann Neurol. 2007. 61:189-98. [View Abstract]
  18. Spurlock G, Bennett E, Chuzhanova N, Thomas N, Jim HP, Side L. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype. J Med Genet. 2009 Jul. 46(7):431-7. [View Abstract]
  19. Shah KN. The diagnostic and clinical significance of café-au-lait macules. Pediatr Clin North Am. 2010. 57:1131-53. [View Abstract]
  20. Karagiannis A, Mikhailidis DP, Athyros VG, et al. Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer. 2007 Dec. 14(4):935-56. [View Abstract]
  21. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA. 2002 Mar 20. 287(11):1427-34. [View Abstract]
  22. Prada CE, Hufnagel RB, Hummel TR, et al. The use of magnetic resonance imaging screening for optic pathway gliomas in children with neurofibromatosis type 1. J Pediatr. 2015. 167:851-6. [View Abstract]
  23. Tucker T, Friedman JM, Friedrich RE, Wenzel R, Fünsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009 Feb. 46(2):81-5. [View Abstract]
  24. Iannicelli E, Rossi G, Almberger M, et al. Integrated imaging in peripheral nerve lesions in type 1 neurofibromatosis. Radiol Med (Torino). 2002 Apr. 103(4):332-43. [View Abstract]
  25. Matsumine A, Kusuzaki K, Nakamura T, Nakazora S, Niimi R, Matsubara T, et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol. 2009 Jul. 135(7):891-900. [View Abstract]
  26. Pacak K, Eisenhofer G, Ahlman H, et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007 Feb. 3(2):92-102. [View Abstract]
  27. Benz MR, Tchekmedyian N, Eilber FC, Federman N, Czernin J, Tap WD. Utilization of positron emission tomography in the management of patients with sarcoma. Curr Opin Oncol. 2009 Jul. 21(4):345-51. [View Abstract]
  28. Levine E, Huntrakoon M, Wetzel LH. Malignant nerve-sheath neoplasms in neurofibromatosis: distinction from benign tumors by using imaging techniques. AJR Am J Roentgenol. 1987 Nov. 149(5):1059-64. [View Abstract]
  29. Wojtkowiak JW, Fouad F, LaLonde DT, et al. Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther. 2008 Jul. 326(1):1-11. [View Abstract]
  30. Ambrosini G, Cheema HS, Seelman S, et al. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther. 2008 Apr. 7(4):890-6. [View Abstract]
  31. Johansson G, Mahller YY, Collins MH, et al. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May. 7(5):1237-45. [View Abstract]
  32. Slomiany MG, Dai L, Bomar PA, Knackstedt TJ, Kranc DA, Tolliver L, et al. Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. Cancer Res. 2009 Jun 15. 69(12):4992-8. [View Abstract]
  33. Hari Kumar KV, Shaikh A, Sandhu AS, Prusty P. Neurofibromatosis 1 with pheochromocytoma. Indian J Endocrinol Metab. 2011 Oct. 15 Suppl 4:S406-8. [View Abstract]
  34. Gerszten PC, Burton SA, Ozhasoglu C, et al. Radiosurgery for benign intradural spinal tumors. Neurosurgery. 2008 Apr. 62(4):887-95; discussion 895-6. [View Abstract]
  35. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003 Aug. 24(4):539-53. [View Abstract]
  36. AAP Committee on Genetics. Health supervision for children with neurofibromatosis. American Academy of Pediatrics Committee on Genetics. Pediatrics. 1995 Aug. 96(2 Pt 1):368-72. [View Abstract]
  37. Chander S, Westphal SM, Zak IT, et al. Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med. 2004 Jul. 29(7):415-8. [View Abstract]
  38. DeClue JE, Cohen BD, Lowy DR. Identification and characterization of the neurofibromatosis type 1 protein product. Proc Natl Acad Sci U S A. 1991 Nov 15. 88(22):9914-8. [View Abstract]
  39. Deliganis AV, Geyer JR, Berger MS. Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma. Neurosurgery. 1996 Jun. 38(6):1114-8; discussion 1118-9. [View Abstract]
  40. Denckla MB, Hofman K, Mazzocco MM, et al. Relationship between T2-weighted hyperintensities (unidentified bright objects) and lower IQs in children with neurofibromatosis-1. Am J Med Genet. 1996 Feb 16. 67(1):98-102. [View Abstract]
  41. Drouet A, Wolkenstein P, Lefaucheur JP, et al. Neurofibromatosis 1-associated neuropathies: a reappraisal. Brain. 2004 Sep. 127:1993-2009. [View Abstract]
  42. Evans DG, Baser ME, McGaughran J, et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002 May. 39(5):311-4. [View Abstract]
  43. Ferner RE, Hughes RA, Hall SM, et al. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet. 2004 Nov. 41(11):837-41. [View Abstract]
  44. Gutmann DH, Collins FS. The neurofibromatosis type 1 gene and its protein product, neurofibromin. Neuron. 1993 Mar. 10(3):335-43. [View Abstract]
  45. Habiby R, Silverman B, Listernick R, et al. Precocious puberty in children with neurofibromatosis type 1. J Pediatr. 1995 Mar. 126(3):364-7. [View Abstract]
  46. Hughes RJ, Scoble JE, Reidy JF. Renal angioplasty in non-atheromatous renal artery stenosis: technical results and clinical outcome in 43 patients. Cardiovasc Intervent Radiol. 2004 Sep-Oct. 27(5):435-40. [View Abstract]
  47. Karadimas P, Hatzispasou E, Bouzas EA. Retinal vascular abnormalities in neurofibromatosis type 1. J Neuroophthalmol. 2003 Dec. 23(4):274-5. [View Abstract]
  48. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000. 5(6):477-85. [View Abstract]
  49. Levy AD, Patel N, Abbott RM, et al. Gastrointestinal stromal tumors in patients with neurofibromatosis: imaging features with clinicopathologic correlation. AJR Am J Roentgenol. 2004 Dec. 183(6):1629-36. [View Abstract]
  50. Listernick R, Ferner RE, Piersall L, et al. Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology. 2004 Nov 23. 63(10):1944-6. [View Abstract]
  51. Nakakura S, Shiraki K, Yasunari T, et al. Quantification and anatomic distribution of choroidal abnormalities in patients with type I neurofibromatosis. Graefes Arch Clin Exp Ophthalmol. 2005 Oct. 243(10):980-4. [View Abstract]
  52. Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference. Arch Neurol. 1988 May. 45(5):575-8. [View Abstract]
  53. North KN, Riccardi V, Samango-Sprouse C, et al. Cognitive function and academic performance in neurofibromatosis. 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology. 1997 Apr. 48(4):1121-7. [View Abstract]
  54. Riccardi VM. Neurofibromatosis. Phenotype, Natural History and Pathogenesis. 2nd ed. Johns Hopkins University Press; 1992.
  55. Scott RM, Smith JL, Robertson RL, Madsen JR, Soriano SG, Rockoff MA. Long-term outcome in children with moyamoya syndrome after cranial revascularization by pial synangiosis. J Neurosurg. 2004 Feb. 100(2 Suppl Pediatrics):142-9. [View Abstract]
  56. Solomon J, Warren K, Dombi E, et al. Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph. 2004 Jul. 28(5):257-65. [View Abstract]
  57. Zacharia TT, Jaramillo D, Poussaint TY, et al. MR imaging of abdominopelvic involvement in neurofibromatosis type 1: a review of 43 patients. Pediatr Radiol. 2005 Mar. 35(3):317-22. [View Abstract]
  58. Zöller M, Rembeck B, Akesson HO, et al. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol. 1995 Mar. 75(2):136-40. [View Abstract]

Café-au-lait spots in a 4-year-old boy.

Axillary freckles.

Café-au-lait spots in a 4-year-old boy.

Axillary freckles.

Inguinal freckles.

Multiple neurofibromas in a 28-year-old man.

Plexiform neurofibroma of the right thigh.

Lisch nodules.

Radial and ulnar bowing and obliteration of the intramedullary spaces.

Radial and ulnar bowing and obliteration of the intramedullary spaces.

Unidentified bright object (UBO) within the brain parenchyma.

Left optic nerve glioma with thickening of the nerve and proptosis.

Below-the-knee amputation for tibial pseudarthrosis.

Café-au-lait spots in a 4-year-old boy.

Axillary freckles.

Inguinal freckles.

Multiple neurofibromas in a 28-year-old man.

Plexiform neurofibroma of the right thigh.

Lisch nodules.

Radial and ulnar bowing and obliteration of the intramedullary spaces.

Unidentified bright object (UBO) within the brain parenchyma.

Left optic nerve glioma with thickening of the nerve and proptosis.

Below-the-knee amputation for tibial pseudarthrosis.

The young woman pictured here has a plexiform neurofibroma of the eyelid.